Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / American Depositary Shares, each representing 6 Ordinary Shares
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
108,766,325
-
Share change
-
-3,421,159
-
Total reported value
-
$224,054,046
-
Put/Call ratio
-
482%
-
Price per share
-
$2.06
-
Number of holders
-
74
-
Value change
-
-$22,141,212
-
Number of buys
-
34
-
Number of sells
-
37
Institutional Holders of ADAPTIMMUNE THERAPEUTICS PLC - American Depositary Shares, each representing 6 Ordinary Shares (ADAPY) as of Q1 2022
As of 31 Mar 2022,
ADAPTIMMUNE THERAPEUTICS PLC - American Depositary Shares, each representing 6 Ordinary Shares (ADAPY) was held by
74 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
108,766,325 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, NEA Management Company, LLC, BAILLIE GIFFORD & CO, BAKER BROS. ADVISORS LP, Long Focus Capital Management, LLC, PFM Health Sciences, LP, Rock Springs Capital Management LP, Endurant Capital Management LP, MORGAN STANLEY, and CITADEL ADVISORS LLC.
This page lists
74
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.